Share Price and Basic Stock Data
Last Updated: February 3, 2026, 3:16 am
| PEG Ratio | 2.84 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Abbott India Ltd operates in the pharmaceuticals sector, with a current market capitalization of ₹58,672 Cr and a share price of ₹27,610. The company reported a trailing twelve months (TTM) revenue of ₹6,714 Cr, which reflects a consistent upward trajectory from ₹5,349 Cr in FY 2023 to ₹6,409 Cr in FY 2025. Quarterly sales have shown resilience, with the latest figure for September 2023 at ₹1,494 Cr, slightly up from ₹1,479 Cr in June 2023. Abbott’s revenue growth is indicative of its robust market positioning and successful product portfolio. The operating profit margin (OPM) stood at 29%, a testament to its operational efficiency compared to industry norms which typically range between 20% to 25%. This performance underscores Abbott’s ability to navigate competitive pressures while enhancing its top line.
Profitability and Efficiency Metrics
Abbott India has demonstrated strong profitability metrics, with a net profit of ₹1,509 Cr and a return on equity (ROE) of 35.7%, significantly higher than the industry average. The company’s net profit margin reached 22.06% in FY 2025, showcasing effective cost management and pricing strategies. The operating profit for the latest quarter was ₹381 Cr, with an OPM of 25%, indicating a stable operational environment. Additionally, the interest coverage ratio (ICR) was remarkably high at 172.37x, reflecting the company’s strong capacity to meet its interest obligations. The cash conversion cycle, which stood at 3 days, highlights Abbott’s efficient working capital management, allowing for quick turnover of inventory and receivables. Overall, these metrics position Abbott favorably within the pharmaceutical landscape.
Balance Sheet Strength and Financial Ratios
Abbott India’s balance sheet exhibits considerable strength, with total assets amounting to ₹5,917 Cr and total liabilities at ₹5,694 Cr, resulting in a healthy equity base. The company’s reserves have increased to ₹3,990 Cr, demonstrating its commitment to reinvestment and growth. Borrowings are relatively low at ₹182 Cr, indicating prudent financial management. The price-to-book value (P/BV) ratio is reported at 15.43x, reflecting a premium valuation compared to typical sector benchmarks. Additionally, the return on capital employed (ROCE) was robust at 46.2%, well above average industry returns. The current ratio of 3.39x signifies strong liquidity, ensuring Abbott can cover its short-term obligations comfortably. These financial ratios affirm Abbott’s financial health and capacity for sustained growth.
Shareholding Pattern and Investor Confidence
The shareholding structure of Abbott India indicates strong promoter confidence, with promoters holding 74.99% of the equity. This stable ownership structure is complemented by a modest foreign institutional investor (FII) presence at 0.16% and domestic institutional investors (DIIs) holding 9.11%. The public shareholding stands at 15.74%, with a total of 71,199 shareholders as of September 2025. The consistent promoter stake suggests a long-term commitment to the company’s strategy and growth. However, the low FII participation may indicate limited international interest, which could be a concern for broader market sentiment. The dividend payout ratio for FY 2025 was 61.59%, reflecting a balanced approach to rewarding shareholders while retaining sufficient earnings for reinvestment. Overall, the shareholding pattern reinforces investor confidence in Abbott India’s strategic direction.
Outlook, Risks, and Final Insight
Abbott India is well-positioned for continued growth, bolstered by its strong revenue trends, profitability metrics, and robust balance sheet. However, potential risks include market competition and regulatory challenges within the pharmaceutical sector, which could impact margins. Additionally, changes in healthcare policies or pricing regulations may pose uncertainties for future earnings. The company’s high ROE and low debt levels are significant strengths, providing a cushion against market volatility. Should Abbott maintain its operational efficiency and continue to innovate within its product lines, it is likely to sustain its growth trajectory. Conversely, failure to adapt to market changes or increased competition could hinder its performance. Overall, investor sentiment remains cautiously optimistic, contingent on the company’s ability to navigate these challenges effectively.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 122 Cr. | 97.0 | 195/84.3 | 27.0 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,449 Cr. | 316 | 479/192 | 71.4 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.6 Cr. | 45.3 | 82.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 73.2 Cr. | 50.0 | 50.0/17.0 | 174 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,474.81 Cr | 1,084.68 | 46.55 | 202.32 | 0.38% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,379 | 1,322 | 1,343 | 1,479 | 1,494 | 1,437 | 1,439 | 1,558 | 1,633 | 1,614 | 1,605 | 1,738 | 1,757 |
| Expenses | 1,036 | 1,010 | 1,063 | 1,124 | 1,113 | 1,049 | 1,109 | 1,167 | 1,194 | 1,178 | 1,176 | 1,293 | 1,255 |
| Operating Profit | 343 | 312 | 280 | 355 | 381 | 388 | 330 | 391 | 439 | 436 | 429 | 446 | 502 |
| OPM % | 25% | 24% | 21% | 24% | 25% | 27% | 23% | 25% | 27% | 27% | 27% | 26% | 29% |
| Other Income | 34 | 44 | 50 | 56 | 56 | 56 | 81 | 67 | 60 | 72 | 76 | 73 | 70 |
| Interest | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 4 | 6 | 8 |
| Depreciation | 17 | 18 | 17 | 17 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 19 | 19 |
| Profit before tax | 355 | 335 | 308 | 390 | 415 | 422 | 390 | 437 | 479 | 488 | 483 | 493 | 546 |
| Tax % | 25% | 26% | 25% | 26% | 25% | 26% | 26% | 25% | 25% | 26% | 24% | 26% | 24% |
| Net Profit | 266 | 247 | 231 | 290 | 313 | 311 | 287 | 328 | 359 | 361 | 367 | 366 | 415 |
| EPS in Rs | 124.95 | 116.16 | 108.91 | 136.59 | 147.27 | 146.35 | 135.09 | 154.36 | 168.76 | 169.78 | 172.73 | 172.18 | 195.43 |
Last Updated: December 28, 2025, 10:34 am
Below is a detailed analysis of the quarterly data for Abbott India Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 1,757.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,738.00 Cr. (Jun 2025) to 1,757.00 Cr., marking an increase of 19.00 Cr..
- For Expenses, as of Sep 2025, the value is 1,255.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1,293.00 Cr. (Jun 2025) to 1,255.00 Cr., marking a decrease of 38.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 502.00 Cr.. The value appears strong and on an upward trend. It has increased from 446.00 Cr. (Jun 2025) to 502.00 Cr., marking an increase of 56.00 Cr..
- For OPM %, as of Sep 2025, the value is 29.00%. The value appears strong and on an upward trend. It has increased from 26.00% (Jun 2025) to 29.00%, marking an increase of 3.00%.
- For Other Income, as of Sep 2025, the value is 70.00 Cr.. The value appears to be declining and may need further review. It has decreased from 73.00 Cr. (Jun 2025) to 70.00 Cr., marking a decrease of 3.00 Cr..
- For Interest, as of Sep 2025, the value is 8.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6.00 Cr. (Jun 2025) to 8.00 Cr., marking an increase of 2.00 Cr..
- For Depreciation, as of Sep 2025, the value is 19.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 19.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 546.00 Cr.. The value appears strong and on an upward trend. It has increased from 493.00 Cr. (Jun 2025) to 546.00 Cr., marking an increase of 53.00 Cr..
- For Tax %, as of Sep 2025, the value is 24.00%. The value appears to be improving (decreasing) as expected. It has decreased from 26.00% (Jun 2025) to 24.00%, marking a decrease of 2.00%.
- For Net Profit, as of Sep 2025, the value is 415.00 Cr.. The value appears strong and on an upward trend. It has increased from 366.00 Cr. (Jun 2025) to 415.00 Cr., marking an increase of 49.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 195.43. The value appears strong and on an upward trend. It has increased from 172.18 (Jun 2025) to 195.43, marking an increase of 23.25.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:20 am
| Metric | Mar 2014n n 15m | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,276 | 2,289 | 2,614 | 2,903 | 3,298 | 3,679 | 4,093 | 4,310 | 4,919 | 5,349 | 5,849 | 6,409 | 6,714 |
| Expenses | 2,009 | 1,977 | 2,250 | 2,505 | 2,774 | 3,074 | 3,336 | 3,388 | 3,832 | 4,143 | 4,396 | 4,714 | 4,902 |
| Operating Profit | 267 | 312 | 365 | 398 | 525 | 605 | 757 | 922 | 1,088 | 1,206 | 1,453 | 1,695 | 1,812 |
| OPM % | 12% | 14% | 14% | 14% | 16% | 16% | 18% | 21% | 22% | 23% | 25% | 26% | 27% |
| Other Income | 49 | 48 | 50 | 57 | 117 | 113 | 114 | 81 | 77 | 154 | 248 | 275 | 291 |
| Interest | 0 | 0 | 3 | 2 | 4 | 2 | 9 | 18 | 19 | 16 | 12 | 11 | 20 |
| Depreciation | 22 | 15 | 14 | 16 | 16 | 17 | 60 | 58 | 66 | 70 | 71 | 72 | 74 |
| Profit before tax | 295 | 344 | 398 | 436 | 621 | 699 | 803 | 926 | 1,080 | 1,274 | 1,618 | 1,887 | 2,009 |
| Tax % | 33% | 34% | 36% | 37% | 35% | 36% | 26% | 25% | 26% | 25% | 26% | 25% | |
| Net Profit | 198 | 229 | 255 | 277 | 401 | 450 | 593 | 691 | 799 | 949 | 1,201 | 1,414 | 1,509 |
| EPS in Rs | 93.39 | 107.75 | 120.12 | 130.19 | 188.82 | 211.93 | 279.04 | 325.04 | 375.87 | 446.80 | 565.30 | 665.64 | 710.12 |
| Dividend Payout % | 25% | 29% | 29% | 31% | 29% | 31% | 90% | 85% | 73% | 73% | 73% | 71% |
YoY Net Profit Growth
| Year | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 11.35% | 8.63% | 44.77% | 12.22% | 31.78% | 16.53% | 15.63% | 18.77% | 26.55% | 17.74% |
| Change in YoY Net Profit Growth (%) | 0.00% | -2.73% | 36.14% | -32.55% | 19.56% | -15.25% | -0.90% | 3.14% | 7.78% | -8.82% |
Abbott India Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2015-2016 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 9% |
| 3 Years: | 9% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 19% |
| 3 Years: | 21% |
| TTM: | 17% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 14% |
| 3 Years: | 21% |
| 1 Year: | 8% |
| Return on Equity | |
|---|---|
| 10 Years: | 30% |
| 5 Years: | 32% |
| 3 Years: | 34% |
| Last Year: | 36% |
Last Updated: September 5, 2025, 2:01 pm
Balance Sheet
Last Updated: December 4, 2025, 2:16 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 |
| Reserves | 767 | 916 | 1,174 | 1,366 | 1,672 | 1,987 | 2,410 | 2,581 | 2,799 | 3,167 | 3,678 | 4,212 | 3,990 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 175 | 153 | 152 | 113 | 83 | 197 | 182 |
| Other Liabilities | 351 | 436 | 421 | 679 | 723 | 932 | 940 | 1,086 | 1,253 | 1,254 | 1,411 | 1,487 | 1,501 |
| Total Liabilities | 1,139 | 1,374 | 1,616 | 2,066 | 2,416 | 2,941 | 3,547 | 3,840 | 4,224 | 4,556 | 5,193 | 5,917 | 5,694 |
| Fixed Assets | 98 | 96 | 108 | 110 | 81 | 105 | 270 | 251 | 271 | 237 | 225 | 336 | 314 |
| CWIP | 1 | 4 | 3 | 6 | 2 | 1 | 2 | 1 | 1 | 4 | 10 | 18 | 23 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 1,040 | 1,274 | 1,505 | 1,950 | 2,333 | 2,835 | 3,275 | 3,589 | 3,952 | 4,315 | 4,958 | 5,563 | 5,357 |
| Total Assets | 1,139 | 1,374 | 1,616 | 2,066 | 2,416 | 2,941 | 3,547 | 3,840 | 4,224 | 4,556 | 5,193 | 5,917 | 5,694 |
Below is a detailed analysis of the balance sheet data for Abbott India Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 21.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 21.00 Cr..
- For Reserves, as of Sep 2025, the value is 3,990.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4,212.00 Cr. (Mar 2025) to 3,990.00 Cr., marking a decrease of 222.00 Cr..
- For Borrowings, as of Sep 2025, the value is 182.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 197.00 Cr. (Mar 2025) to 182.00 Cr., marking a decrease of 15.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1,501.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,487.00 Cr. (Mar 2025) to 1,501.00 Cr., marking an increase of 14.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 5,694.00 Cr.. The value appears to be improving (decreasing). It has decreased from 5,917.00 Cr. (Mar 2025) to 5,694.00 Cr., marking a decrease of 223.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 314.00 Cr.. The value appears to be declining and may need further review. It has decreased from 336.00 Cr. (Mar 2025) to 314.00 Cr., marking a decrease of 22.00 Cr..
- For CWIP, as of Sep 2025, the value is 23.00 Cr.. The value appears strong and on an upward trend. It has increased from 18.00 Cr. (Mar 2025) to 23.00 Cr., marking an increase of 5.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 5,357.00 Cr.. The value appears to be declining and may need further review. It has decreased from 5,563.00 Cr. (Mar 2025) to 5,357.00 Cr., marking a decrease of 206.00 Cr..
- For Total Assets, as of Sep 2025, the value is 5,694.00 Cr.. The value appears to be declining and may need further review. It has decreased from 5,917.00 Cr. (Mar 2025) to 5,694.00 Cr., marking a decrease of 223.00 Cr..
Notably, the Reserves (3,990.00 Cr.) exceed the Borrowings (182.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014n n 15m | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 267.00 | 312.00 | 365.00 | 398.00 | 525.00 | 605.00 | 582.00 | 769.00 | -151.00 | -112.00 | -82.00 | -196.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 18 | 21 | 20 | 22 | 29 | 27 | 28 | 21 | 21 | 22 | 20 | 22 |
| Inventory Days | 101 | 107 | 91 | 107 | 112 | 106 | 83 | 110 | 94 | 80 | 70 | 92 |
| Days Payable | 38 | 54 | 56 | 101 | 92 | 116 | 104 | 116 | 122 | 109 | 114 | 110 |
| Cash Conversion Cycle | 80 | 74 | 54 | 28 | 49 | 17 | 8 | 14 | -6 | -8 | -24 | 3 |
| Working Capital Days | 36 | 30 | 32 | 21 | 63 | 22 | 10 | 7 | -7 | -8 | -14 | 97 |
| ROCE % | 39% | 40% | 38% | 34% | 41% | 37% | 35% | 35% | 38% | 41% | 46% | 46% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| SBI Large & Midcap Fund | 274,878 | 2.13 | 797.83 | 155,000 | 2025-10-30 02:04:49 | 77.34% |
| Axis Midcap Fund | 162,848 | 1.49 | 472.67 | 165,040 | 2026-01-26 05:00:11 | -1.33% |
| Canara Robeco Large and Mid Cap Fund | 145,836 | 1.65 | 423.29 | 144,836 | 2026-01-25 01:39:51 | 0.69% |
| Nippon India Multi Cap Fund | 105,953 | 0.61 | 307.53 | 87,483 | 2026-01-25 09:45:10 | 21.11% |
| SBI MNC Fund | 75,000 | 3.73 | 217.69 | 80,000 | 2026-01-26 05:04:32 | -6.25% |
| PGIM India Midcap Fund | 74,300 | 1.91 | 215.66 | N/A | N/A | N/A |
| Nippon India Pharma Fund | 74,187 | 2.61 | 215.33 | 68,677 | 2026-01-25 01:59:43 | 8.02% |
| SBI Innovative Opportunities Fund | 60,032 | 2.91 | 174.24 | N/A | N/A | N/A |
| Franklin India Mid Cap Fund | 52,304 | 1.18 | 151.81 | N/A | N/A | N/A |
| SBI Healthcare Opportunities Fund | 40,000 | 2.91 | 116.1 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 665.62 | 565.28 | 446.78 | 375.86 | 325.04 |
| Diluted EPS (Rs.) | 665.62 | 565.28 | 446.78 | 375.86 | 325.04 |
| Cash EPS (Rs.) | 699.41 | 598.77 | 479.71 | 406.96 | 352.38 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 1992.07 | 1740.65 | 1500.49 | 1326.96 | 1224.55 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 1992.07 | 1740.65 | 1500.49 | 1326.96 | 1224.55 |
| Dividend / Share (Rs.) | 475.00 | 410.00 | 325.00 | 275.00 | 275.00 |
| Revenue From Operations / Share (Rs.) | 3016.07 | 2752.43 | 2517.05 | 2314.95 | 2028.24 |
| PBDIT / Share (Rs.) | 927.14 | 800.64 | 639.90 | 548.20 | 471.70 |
| PBIT / Share (Rs.) | 893.36 | 767.15 | 606.97 | 517.10 | 444.34 |
| PBT / Share (Rs.) | 887.98 | 761.29 | 599.44 | 508.11 | 435.74 |
| Net Profit / Share (Rs.) | 665.62 | 565.28 | 446.78 | 375.86 | 325.03 |
| PBDIT Margin (%) | 30.74 | 29.08 | 25.42 | 23.68 | 23.25 |
| PBIT Margin (%) | 29.61 | 27.87 | 24.11 | 22.33 | 21.90 |
| PBT Margin (%) | 29.44 | 27.65 | 23.81 | 21.94 | 21.48 |
| Net Profit Margin (%) | 22.06 | 20.53 | 17.75 | 16.23 | 16.02 |
| Return on Networth / Equity (%) | 33.41 | 32.47 | 29.77 | 28.32 | 26.54 |
| Return on Capital Employeed (%) | 42.09 | 42.33 | 38.50 | 36.37 | 33.60 |
| Return On Assets (%) | 23.90 | 23.12 | 20.84 | 18.90 | 17.98 |
| Asset Turnover Ratio (%) | 1.15 | 1.20 | 1.22 | 1.22 | 1.17 |
| Current Ratio (X) | 3.39 | 2.42 | 2.51 | 3.20 | 3.41 |
| Quick Ratio (X) | 2.76 | 1.96 | 1.97 | 2.63 | 2.72 |
| Inventory Turnover Ratio (X) | 8.54 | 9.22 | 0.83 | 0.70 | 0.72 |
| Dividend Payout Ratio (NP) (%) | 61.59 | 57.49 | 61.54 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 58.61 | 54.27 | 57.32 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | 38.41 | 42.51 | 38.46 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 41.39 | 45.73 | 42.68 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 172.37 | 136.66 | 85.04 | 60.99 | 54.83 |
| Interest Coverage Ratio (Post Tax) (X) | 124.75 | 97.48 | 60.38 | 42.82 | 38.78 |
| Enterprise Value (Cr.) | 63674.71 | 55125.76 | 44996.86 | 34862.11 | 29441.84 |
| EV / Net Operating Revenue (X) | 9.93 | 9.42 | 8.41 | 7.09 | 6.83 |
| EV / EBITDA (X) | 32.32 | 32.40 | 33.09 | 29.93 | 29.37 |
| MarketCap / Net Operating Revenue (X) | 10.19 | 9.79 | 8.77 | 7.65 | 7.39 |
| Retention Ratios (%) | 38.40 | 42.50 | 38.45 | 0.00 | 0.00 |
| Price / BV (X) | 15.43 | 15.48 | 14.72 | 13.34 | 12.24 |
| Price / Net Operating Revenue (X) | 10.19 | 9.79 | 8.77 | 7.65 | 7.39 |
| EarningsYield | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
After reviewing the key financial ratios for Abbott India Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 665.62. This value is within the healthy range. It has increased from 565.28 (Mar 24) to 665.62, marking an increase of 100.34.
- For Diluted EPS (Rs.), as of Mar 25, the value is 665.62. This value is within the healthy range. It has increased from 565.28 (Mar 24) to 665.62, marking an increase of 100.34.
- For Cash EPS (Rs.), as of Mar 25, the value is 699.41. This value is within the healthy range. It has increased from 598.77 (Mar 24) to 699.41, marking an increase of 100.64.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1,992.07. It has increased from 1,740.65 (Mar 24) to 1,992.07, marking an increase of 251.42.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1,992.07. It has increased from 1,740.65 (Mar 24) to 1,992.07, marking an increase of 251.42.
- For Dividend / Share (Rs.), as of Mar 25, the value is 475.00. This value exceeds the healthy maximum of 3. It has increased from 410.00 (Mar 24) to 475.00, marking an increase of 65.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 3,016.07. It has increased from 2,752.43 (Mar 24) to 3,016.07, marking an increase of 263.64.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 927.14. This value is within the healthy range. It has increased from 800.64 (Mar 24) to 927.14, marking an increase of 126.50.
- For PBIT / Share (Rs.), as of Mar 25, the value is 893.36. This value is within the healthy range. It has increased from 767.15 (Mar 24) to 893.36, marking an increase of 126.21.
- For PBT / Share (Rs.), as of Mar 25, the value is 887.98. This value is within the healthy range. It has increased from 761.29 (Mar 24) to 887.98, marking an increase of 126.69.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 665.62. This value is within the healthy range. It has increased from 565.28 (Mar 24) to 665.62, marking an increase of 100.34.
- For PBDIT Margin (%), as of Mar 25, the value is 30.74. This value is within the healthy range. It has increased from 29.08 (Mar 24) to 30.74, marking an increase of 1.66.
- For PBIT Margin (%), as of Mar 25, the value is 29.61. This value exceeds the healthy maximum of 20. It has increased from 27.87 (Mar 24) to 29.61, marking an increase of 1.74.
- For PBT Margin (%), as of Mar 25, the value is 29.44. This value is within the healthy range. It has increased from 27.65 (Mar 24) to 29.44, marking an increase of 1.79.
- For Net Profit Margin (%), as of Mar 25, the value is 22.06. This value exceeds the healthy maximum of 10. It has increased from 20.53 (Mar 24) to 22.06, marking an increase of 1.53.
- For Return on Networth / Equity (%), as of Mar 25, the value is 33.41. This value is within the healthy range. It has increased from 32.47 (Mar 24) to 33.41, marking an increase of 0.94.
- For Return on Capital Employeed (%), as of Mar 25, the value is 42.09. This value is within the healthy range. It has decreased from 42.33 (Mar 24) to 42.09, marking a decrease of 0.24.
- For Return On Assets (%), as of Mar 25, the value is 23.90. This value is within the healthy range. It has increased from 23.12 (Mar 24) to 23.90, marking an increase of 0.78.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.15. It has decreased from 1.20 (Mar 24) to 1.15, marking a decrease of 0.05.
- For Current Ratio (X), as of Mar 25, the value is 3.39. This value exceeds the healthy maximum of 3. It has increased from 2.42 (Mar 24) to 3.39, marking an increase of 0.97.
- For Quick Ratio (X), as of Mar 25, the value is 2.76. This value exceeds the healthy maximum of 2. It has increased from 1.96 (Mar 24) to 2.76, marking an increase of 0.80.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 8.54. This value exceeds the healthy maximum of 8. It has decreased from 9.22 (Mar 24) to 8.54, marking a decrease of 0.68.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 61.59. This value exceeds the healthy maximum of 50. It has increased from 57.49 (Mar 24) to 61.59, marking an increase of 4.10.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 58.61. This value exceeds the healthy maximum of 50. It has increased from 54.27 (Mar 24) to 58.61, marking an increase of 4.34.
- For Earning Retention Ratio (%), as of Mar 25, the value is 38.41. This value is below the healthy minimum of 40. It has decreased from 42.51 (Mar 24) to 38.41, marking a decrease of 4.10.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 41.39. This value is within the healthy range. It has decreased from 45.73 (Mar 24) to 41.39, marking a decrease of 4.34.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 172.37. This value is within the healthy range. It has increased from 136.66 (Mar 24) to 172.37, marking an increase of 35.71.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 124.75. This value is within the healthy range. It has increased from 97.48 (Mar 24) to 124.75, marking an increase of 27.27.
- For Enterprise Value (Cr.), as of Mar 25, the value is 63,674.71. It has increased from 55,125.76 (Mar 24) to 63,674.71, marking an increase of 8,548.95.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 9.93. This value exceeds the healthy maximum of 3. It has increased from 9.42 (Mar 24) to 9.93, marking an increase of 0.51.
- For EV / EBITDA (X), as of Mar 25, the value is 32.32. This value exceeds the healthy maximum of 15. It has decreased from 32.40 (Mar 24) to 32.32, marking a decrease of 0.08.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 10.19. This value exceeds the healthy maximum of 3. It has increased from 9.79 (Mar 24) to 10.19, marking an increase of 0.40.
- For Retention Ratios (%), as of Mar 25, the value is 38.40. This value is within the healthy range. It has decreased from 42.50 (Mar 24) to 38.40, marking a decrease of 4.10.
- For Price / BV (X), as of Mar 25, the value is 15.43. This value exceeds the healthy maximum of 3. It has decreased from 15.48 (Mar 24) to 15.43, marking a decrease of 0.05.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 10.19. This value exceeds the healthy maximum of 3. It has increased from 9.79 (Mar 24) to 10.19, marking an increase of 0.40.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Abbott India Ltd:
- Net Profit Margin: 22.06%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 42.09% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 33.41% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 124.75
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.76
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 38.5 (Industry average Stock P/E: 46.55)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 22.06%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 3, Corporate Park, Mumbai Maharashtra 400071 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Munir Shaikh | Chairman |
| Mr. Kartik Rajendran | Managing Director |
| Mr. Kaiyomarz Marfatia | Non Executive Director |
| Mr. Ambati Venu | Non Executive Director |
| Ms. Alison Davies | Non Executive Director |
| Ms. Anisha Motwani | Independent Director |
| Ms. Shalini Kamath | Independent Director |
| Mr. Sudarshan Jain | Independent Director |
FAQ
What is the intrinsic value of Abbott India Ltd?
Abbott India Ltd's intrinsic value (as of 02 February 2026) is ₹23986.75 which is 12.22% lower the current market price of ₹27,325.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹58,066 Cr. market cap, FY2025-2026 high/low of ₹37,000/25,950, reserves of ₹3,990 Cr, and liabilities of ₹5,694 Cr.
What is the Market Cap of Abbott India Ltd?
The Market Cap of Abbott India Ltd is 58,066 Cr..
What is the current Stock Price of Abbott India Ltd as on 02 February 2026?
The current stock price of Abbott India Ltd as on 02 February 2026 is ₹27,325.
What is the High / Low of Abbott India Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Abbott India Ltd stocks is ₹37,000/25,950.
What is the Stock P/E of Abbott India Ltd?
The Stock P/E of Abbott India Ltd is 38.5.
What is the Book Value of Abbott India Ltd?
The Book Value of Abbott India Ltd is 1,888.
What is the Dividend Yield of Abbott India Ltd?
The Dividend Yield of Abbott India Ltd is 1.74 %.
What is the ROCE of Abbott India Ltd?
The ROCE of Abbott India Ltd is 46.2 %.
What is the ROE of Abbott India Ltd?
The ROE of Abbott India Ltd is 35.7 %.
What is the Face Value of Abbott India Ltd?
The Face Value of Abbott India Ltd is 10.0.